Harvard Bioscience (HBIO) Stock Statistics & Valuation Metrics

Harvard Bioscience has a market cap or net worth of $17.00M. The enterprise value is $158.44M.

Harvard Bioscience has 44.07M shares outstanding. The number of shares has decreased by -2.65% in one year.

Harvard Bioscience’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -6.02%.

The current PE Ratio of Harvard Bioscience is -7.41. Harvard Bioscience’s PEG ratio is -0.03.

In the last 12 months, Harvard Bioscience had revenue of $94.14M and earned -$12.40M in profits. Earnings per share was -$0.29.

In the last 12 months, operating cash flow was $1.44M and capital expenditures -$2.64M, giving a free cash flow of -$1.20M billion.

Harvard Bioscience pays an annual dividend of $1.34, resulting in a dividend yield of

Harvard Bioscience upcoming earnings date is May 13, 2025, After Close.

Harvard Bioscience as a current ratio of 0.82, with Debt / Equity ratio of 0.70

In the past 12 months, Harvard Bioscience has paid $740.00K in taxes.

Harvard Bioscience EV to EBITDA ratio is -101.81, with an EV/FCF ratio of -109.84.

Harvard Bioscience has $4.11M in cash and marketable securities with $44.49M in debt, giving a net cash position of $40.39M billion.

Gross margin is 58.18%, with operating margin of -6.60%, and net profit margin of -13.18%.

The average price target for Harvard Bioscience is $4.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy